News

New data from more than 1,100 patients show that the investigational migraine therapy, when taken early, produced pain-free results at two and four hours, as well as a

The approved supplemental new drug application was based on the results of the company’s successful phase III trial in 510 community-acquired pneumonia (CAP) patients comparing a five-day treatment

In the study, a 30-day course of oral Cethromycin was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Bayer’s Cipro

AeroLEF met the primary endpoint of the study, showing a statistically significant difference in SPRID4, a summary of the combined changes in pain relief and in pain intensity

University College London’s Institute of Ophthalmology and Moorfields Eye Hospital, with funding from the UK Department of Health, are trialing the treatment in adults and children with a

In January, Hi-Tech Pharmacal said that it had entered into an agreement with Victory to market and distribute Naprelan extended release tablets, with the ultimate goal of selling

CyDex’s Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs. CyDex has granted Proteolix global rights to Captisol for a formulation of PR-171

Under the terms of the collaboration, Emerillon will provide Alethia with a list of genetic loci that are associated with an osteoporotic phenotype in mice. In return, Alethia

Inex will be seeking opportunities outside the pharmaceutical industry under new management, according to the company. As part of the spin-out, Inex common shares were consolidated on the